![Javier Barallobre-Barreiro](/newimages/folsm/person-profile/scms/javier-barallobre-barreiro.x5dd3a028.png?f=webp)
Dr Javier Barallobre-Barreiro
BHF Intermediate Fellow
Contact details
Biography
Javier Barallobre-Barreiro is a Molecular Biologist by training and the main focus of his research is the biology of cardiac extracellular matrix. Javier joined King’s in 2011 as a Postdoctoral Researcher. He improved the available strategies to study the cardiovascular extracellular matrix and investigated the role of extracellular matrix protein fragmentation in cardiac disease. In 2016 he was awarded a Career Establishment Fellowship at King’s, and in 2019 he obtained a British Heart Foundation Intermediate Basic Science Research Fellowship, focused on the investigation of the roles of extracellular matrix remodelling in heart failure using preclinical models and clinical samples.
Research
![Vascular Proteomics 780x450](/newimages/research/thumb/vascular-proteomics-780x450.x34dc5371.png?crop=780,440,0,5&width=380&height=215&fit=crop&f=webp)
Vascular Proteomics
Our group uses proteomics in combination with other -omics technologies, such as metabolomics, lipidomics and microRNA profiling, to integrate biological information in disease-specific networks that drive pathopysiological changes.
News
Beta-blockers reduce heart proteoglycan content potentially providing newly discovered health benefits
Researchers discover that beta-blockers can prevent build-up of proteoglycans, a group of proteins that accumulate in the heart of patients with heart failure.
![Cardiac cell SEM colour 780x440](/newimages/folsm/cardiac-cell-sem-colour-780x440.xd1536f38.png?f=webp)
Research
![Vascular Proteomics 780x450](/newimages/research/thumb/vascular-proteomics-780x450.x34dc5371.png?crop=780,440,0,5&width=380&height=215&fit=crop&f=webp)
Vascular Proteomics
Our group uses proteomics in combination with other -omics technologies, such as metabolomics, lipidomics and microRNA profiling, to integrate biological information in disease-specific networks that drive pathopysiological changes.
News
Beta-blockers reduce heart proteoglycan content potentially providing newly discovered health benefits
Researchers discover that beta-blockers can prevent build-up of proteoglycans, a group of proteins that accumulate in the heart of patients with heart failure.
![Cardiac cell SEM colour 780x440](/newimages/folsm/cardiac-cell-sem-colour-780x440.xd1536f38.png?f=webp)